Apnimed CEO holds stock options on 1,186,278 shares
Apnimed, Inc. (APMD) reported the initial beneficial ownership of its Chief Executive Officer, Kevin Robert Lind, in a Form 3.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Apnimed, Inc. (APMD) reported the initial beneficial ownership of its Chief Executive Officer, Kevin Robert Lind, in a Form 3. He holds stock options giving the right to purchase Class A Common Stock at exercise prices of $9.50 and $8.15, expiring in 2035 and 2036, respectively. These options cover 74,128 and 1,186,278 underlying shares and vest over time based on his continuous service, with 25% vesting after 12 months from the stated start dates and the remainder vesting in installments over the following 36 months.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Lind Kevin Robert
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Option (Right to Buy) F2 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 1,260,406 contracts (Direct)
Footnotes (2)
- F1. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F2. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Underlying Shares (Option 1): 74,128 shares
Exercise Price (Option 1): $9.5000 per share
Expiration Date (Option 1): 2035-03-06
+5 more
8 metrics
Underlying Shares (Option 1)
74,128 shares
Underlying Class A Common Stock for stock option at $9.5000 exercise price
Exercise Price (Option 1)
$9.5000 per share
Stock Option (Right to Buy) expiring March 6, 2035
Expiration Date (Option 1)
2035-03-06
Expiration of stock option with 74,128 underlying shares
Underlying Shares (Option 2)
1,186,278 shares
Underlying Class A Common Stock for stock option at $8.1500 exercise price
Exercise Price (Option 2)
$8.1500 per share
Stock Option (Right to Buy) expiring June 23, 2036
Expiration Date (Option 2)
2036-06-23
Expiration of stock option with 1,186,278 underlying shares
Vesting Schedule (Option F1)
25% after 12 months, remainder over 36 months
Quarterly vesting after March 6, 2025, subject to continuous service
Vesting Schedule (Option F2)
25% after 12 months, remainder over 36 months
Monthly vesting after June 1, 2026, subject to continuous service
Key Terms
Stock Option (Right to Buy), Class A Common Stock, exercise price, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title is listed as Stock Option (Right to Buy)"
Class A Common Stock financial
"underlying security title is Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
exercise price financial
"conversion or exercise price is shown as 9.5000 and 8.1500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"25% of the shares subject to such option vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Apnimed (APMD) disclose in this Form 3 filing?
Apnimed (APMD) discloses its CEO Kevin Robert Lind’s initial beneficial ownership in company securities, specifically stock options to acquire Class A Common Stock, including their exercise prices, expiration dates, and time-based vesting schedules tied to his continuous service.
What are the exercise prices of the stock options held by Apnimed (APMD) CEO Kevin Lind?
The reported stock options held by Kevin Lind have exercise prices of $9.50 and $8.15 per share. These prices are the amounts payable per share to acquire Apnimed Class A Common Stock upon exercise of the respective options.
When do Kevin Lind’s Apnimed (APMD) stock options expire?
The reported stock options for Apnimed CEO Kevin Lind expire on March 6, 2035 and June 23, 2036. After these expiration dates, any unexercised portion of the respective options would no longer be exercisable under the disclosed terms.
How do the vesting terms work for Kevin Lind’s Apnimed (APMD) stock options?
Each option vests 25% after 12 months of continuous service from its start date, with the remaining 75% vesting in substantially equal quarterly or monthly installments over the next 36 months, conditioned on his continuous service with Apnimed.
Does this Apnimed (APMD) Form 3 show any insider buying or selling?
No buying or selling is reported; the Form 3 lists existing stock option holdings for Kevin Lind. The transactions are classified as holdings entries, indicating positions rather than purchases or sales of Apnimed’s Class A Common Stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
